U.S. IT Stock News

NYSE:HRI
NYSE:HRITrade Distributors

Herc Holdings’ Record Acquisition Puts Integration Progress And Valuation In Focus

Herc Holdings (NYSE:HRI) has completed its largest acquisition to date, expanding its equipment rental footprint across local markets. The company is now concentrating on post-merger integration, including combining operations, systems, and teams across the enlarged network. Management is prioritizing cost synergies, higher used equipment sales, and branch network changes following the closing of the deal. Herc Holdings runs a broad equipment rental business that serves construction,...
NYSE:YALA
NYSE:YALAInteractive Media and Services

Yalla Group (YALA) Valuation Check As MENA Expansion And Analyst Optimism Draw Fresh Attention

Yalla Group (YALA) is back in focus as recent coverage highlights its expansion across the Middle East and North Africa, with analyst sentiment and culturally tailored apps drawing fresh attention to the stock. See our latest analysis for Yalla Group. Yalla Group’s share price has been relatively steady in the short term, with a 1-day share price return of 1.67% decline and a 7-day share price return of 3.15% decline. Its 1-year total shareholder return of 79.7% and 3-year total shareholder...
NYSE:HCI
NYSE:HCIInsurance

HCI Group (HCI) Is Up 13.0% After Record 2025 Results, Exzeo IPO And $80M Buyback Plan

HCI Group, Inc. has reported past fourth-quarter 2025 revenue of US$246.24 million and net income of US$97.65 million, alongside full-year revenue of US$900.95 million and net income of US$299.01 million, with earnings per share from continuing operations rising sharply versus the prior year. Beyond these record insurance results, management highlighted the successful IPO of its Exzeo technology platform and an upcoming US$80 million share repurchase program as key milestones reshaping the...
NYSE:SIG
NYSE:SIGSpecialty Retail

How Lab-Grown Diamond Margins and Raised Guidance Will Impact Signet Jewelers (SIG) Investors

Recently, Signet Jewelers reported past quarterly results showing roughly 3% growth in same-store and net sales, alongside a very large rise in adjusted earnings, and raised its full-year guidance, helped by stronger lab-grown diamond sales that now form a substantial share of fashion and bridal revenue. This shift toward higher-margin lab-grown diamonds and improved inventory management highlights how Signet’s evolving product mix and operations may be reshaping its underlying business...
NYSE:SBR
NYSE:SBROil and Gas

The Bull Case For Sabine Royalty Trust (SBR) Could Change Following Diverging 2025 Income And Reserve Value Trends

Sabine Royalty Trust recently reported full-year 2025 results, with revenue of US$77.53 million and net income of US$73.44 million, both lower than the prior year. Alongside lower royalty and distributable income driven by weaker oil prices and production, the trust disclosed that the present value of future net revenue from proved developed reserves increased year over year. Next, we will examine how the decline in royalty and distributable income shapes Sabine Royalty Trust’s investment...
NYSE:PMT
NYSE:PMTMortgage REITs

Will Strong Q4 Results and US$2.8 Billion Securitizations Change PennyMac Mortgage Investment Trust's (PMT) Narrative?

PennyMac Mortgage Investment Trust recently reported fourth quarter results, posting earnings per share of US$0.48, an annualized return on common equity of 13%, eight private label securitizations totaling US$2.80 billion, more than US$180 million of retained subordinate bond investments, and issued US$150 million of exchangeable senior notes to bolster liquidity. This combination of earnings strength, expanded securitization activity, and fresh exchangeable debt financing highlights how...
NYSE:GLP
NYSE:GLPOil and Gas

Global Partners’ Terminal Push and Higher Payouts Might Change The Case For Investing In GLP

Global Partners LP has reported past fourth-quarter 2025 results with sales of US$4,647.88 million and net income of US$20.13 million, alongside full-year sales of US$18,561.42 million and net income of US$79.22 million, reflecting higher quarterly revenue but lower annual earnings versus the prior year. Beyond the headline numbers, the period highlighted stronger Wholesale segment margins, the Providence terminal acquisition, expansion into the Houston bunkering market, and the seventeenth...
NYSE:SEI
NYSE:SEIEnergy Services

How Solaris’ Data Center Power Shift, 2025 Results and New CFO At SEI Have Changed Its Investment Story

Solaris Energy Infrastructure, Inc. reported past fourth-quarter 2025 sales of US$88.94 million and revenue of US$179.7 million, alongside a quarterly net loss of US$1.66 million but full-year 2025 net income of US$30.17 million on revenue of US$622.21 million, while approving a US$0.12 first-quarter 2026 dividend and appointing Stephan E. Tompsett as Chief Financial Officer. These results underscore how Solaris’ Power Solutions pivot, long-term hyperscale data center power contracts, and...
NYSE:BEKE
NYSE:BEKEReal Estate

Did Index Inclusion and 2026 Cost Push Just Shift KE Holdings' (BEKE) Investment Narrative?

KE Holdings was recently added to the Hang Seng China Enterprises Index, while institutions highlighted the company's planned cost optimization in its core property transaction operations for 2026. This combination of benchmark index inclusion and an efficiency push in its real estate platform could meaningfully reshape how investors assess its earnings quality and business mix. Next, we will examine how KE Holdings’ Hang Seng China Enterprises Index inclusion may influence its existing...
NYSE:DNOW
NYSE:DNOWTrade Distributors

Assessing DNOW (DNOW) Valuation After Sales Growth, Net Loss And Completed Share Buyback Program

DNOW (DNOW) just reported fourth quarter and full year 2025 results that combined higher sales with a swing to net loss, along with an update that its previously announced share repurchase program is now completed. See our latest analysis for DNOW. At a share price of US$11.78, DNOW’s recent 7 day share price return of an 11% decline and 30 day share price return of a 22% decline suggest fading momentum after the earnings driven swing from profit to loss. This is also reflected in its 1 year...
NYSE:FBP
NYSE:FBPBanks

Assessing First BanCorp (FBP) Valuation As Labor Shortages Raise Credit And Operational Risks

Recent reports of labor shortages affecting Puerto Rico, the U.S., the Virgin Islands, and other markets have pushed First BanCorp (FBP) into focus as investors reassess its credit and operational risk profile. See our latest analysis for First BanCorp. The latest labor shortage headlines arrive after a sharp 4.8% one day share price decline and a 7.0% 7 day share price return. However, First BanCorp’s 1 year total shareholder return of 12.4% and 5 year total shareholder return of 124.8%...
NasdaqGM:SUPN
NasdaqGM:SUPNPharmaceuticals

Supernus Pharmaceuticals (SUPN) Is Up 7.6% After Record Sales But 2025 Net Loss And Cautious 2026 Outlook

In February 2026, Supernus Pharmaceuticals reported fourth-quarter 2025 revenue of US$211.57 million and record full-year 2025 revenue of US$718.95 million, but swung to a full-year net loss of US$38.55 million and guided 2026 operating earnings to a range of US$0–US$30 million on expected total revenues of US$840–US$870 million. The results highlighted strong contributions from newer CNS products such as Qelbree, GOCOVRI, ZURZUVAE, and newly approved ONAPGO, alongside the completed Sage...
NasdaqGS:POOL
NasdaqGS:POOLRetail Distributors

Pool Highlights Resilience As Growth Shifts To Maintenance And Buybacks

Pool Corporation (NasdaqGS:POOL) is highlighting its resilience in a tough pool industry backdrop, with flat revenues and weakness in new pool construction. The company is leaning on pricing discipline, supply chain initiatives, and digital efforts to support gross margins and customer service. Ongoing acquisition activity remains part of Pool's growth playbook as it looks to expand its reach and capabilities. Pool, a major distributor of swimming pool supplies, equipment, and related...
NasdaqCM:THRY
NasdaqCM:THRYMedia

Is Thryv (THRY) Quietly Rewriting Its Story With ESOP Shares And Improving SaaS Margins?

In late February 2026, Thryv Holdings filed an US$8.15 million shelf registration for 2,179,185 common shares tied to its ESOP and reported fourth-quarter 2025 results showing quarterly sales of US$191.62 million, a net loss of US$9.66 million, and full-year 2025 sales of US$785.02 million with net income of US$0.31 million. Beyond the headline figures, the results underscored Thryv’s rapid pivot toward higher-margin SaaS and AI-powered tools, with SaaS revenue rising sharply, margins...
NasdaqGS:OPCH
NasdaqGS:OPCHHealthcare

Is OPCH’s Enlarged Buyback and Reaffirmed 2026 Outlook Reframing Its Capital Return Story?

Option Care Health, Inc. recently reported its fourth-quarter and full-year 2025 results, with Q4 sales rising to US$1,465.45 million while net income eased slightly to US$58.5 million, and full-year sales increasing to US$5.65 billion alongside modestly higher earnings per share from continuing operations. Alongside these results, the company reaffirmed its 2026 outlook and expanded its share repurchase authorization to US$1 billion, highlighting management’s focus on capital returns even...
NasdaqGS:ACHC
NasdaqGS:ACHCHealthcare

Acadia Healthcare Company (ACHC) Is Up 39.6% After Massive Goodwill Impairment And Cautious 2026 Guidance – Has The Bull Case Changed?

In the fourth quarter and full year 2025, Acadia Healthcare reported higher revenue but swung to a net loss after recording a very large, non-cash goodwill impairment charge of US$996.2 million and issuing 2026 revenue guidance of US$3.37 billion to US$3.45 billion with flat to 1% same-facility volume growth. Management is pivoting from rapid bed expansion to sharpening operational performance at newer facilities, while also managing pressure from New York Medicaid policy changes that are...
NasdaqGM:GDS
NasdaqGM:GDSIT

A Look At GDS Holdings (NasdaqGM:GDS) Valuation After Recent Share Price Volatility

GDS Holdings (NasdaqGM:GDS) has drawn attention after recent share price swings, with a 1 day decline of 1.1% and an 8.4% drop over the past week reshaping short term sentiment. See our latest analysis for GDS Holdings. The recent 1 day and 1 week share price declines come after a stronger 90 day share price return of 21.61% and a 1 year total shareholder return of 8.57%. This may hint at cooling momentum following a solid rebound phase. If GDS Holdings has you thinking about where...
NasdaqGS:FHB
NasdaqGS:FHBBanks

Is First Hawaiian (FHB) Using Segment Realignment And Buybacks To Quietly Redefine Its Core Strategy?

First Hawaiian, Inc. recently filed its 2025 10-K, detailing a shift to two core segments, Retail Banking and Commercial Banking, alongside US$129.9 million in dividends and US$100.0 million in share repurchases, reinforcing its current capital allocation priorities. The combination of segment realignment and sizeable capital returns highlights how management is repositioning the bank’s business mix while returning excess capital to shareholders. Next, we’ll examine how the new Retail and...
NYSE:CBZ
NYSE:CBZProfessional Services

Is CBIZ’s Slowing Organic Growth And Cautious Outlook Altering The Investment Case For CBIZ (CBZ)?

In February 2026, CBIZ, Inc. reported fourth-quarter 2025 results showing sales of US$542.66 million and a net loss of US$79.42 million, alongside full-year 2025 sales of US$2.76 billion and net income of US$115.44 million, and issued 2026 revenue guidance of US$2.8 billion to US$2.9 billion while expanding its share repurchase activity. Beneath the strong headline growth driven by acquisitions such as Marcum, investors focused on weak organic expansion, margin pressure, and cautious 2026...
NasdaqGS:ARWR
NasdaqGS:ARWRBiotechs

Assessing Arrowhead Pharmaceuticals (ARWR) Valuation As Its RNAi Pipeline Advances To Phase 3 With Big Pharma Partners

Arrowhead Pharmaceuticals (ARWR) is back in focus as investors react to progress in its RNA interference drug pipeline, including two therapies in Phase 3 trials and multiple partnerships with large pharmaceutical partners. See our latest analysis for Arrowhead Pharmaceuticals. The recent excitement around Arrowhead’s RNAi pipeline and partnerships comes after a choppy few weeks for the stock, with a 1 month share price return of an 8.74% decline but a 90 day share price return of 12.48%...
NasdaqGM:PRCT
NasdaqGM:PRCTMedical Equipment

PROCEPT BioRobotics (PRCT) Is Down 16.8% After Cutting 2026 Outlook And Widening Q4 Losses

In late February 2026, PROCEPT BioRobotics reported Q4 2025 results showing sales rising to US$76.38 million but a wider quarterly net loss of US$29.85 million, alongside resetting 2026 revenue guidance to US$390 million–US$410 million and issuing new 2027 targets that include 25%–30% revenue growth and a 68%–70% gross margin. While the company pointed to record procedure volumes, stronger handpiece pricing and a path toward improved margins, investors also had to weigh a larger loss profile...
NYSE:EXPD
NYSE:EXPDLogistics

A Look At Expeditors (EXPD) Valuation After New US$3b Buyback And 2025 Earnings Release

Expeditors International of Washington (EXPD) is back in focus after pairing its full year 2025 earnings release with a new US$3b share repurchase authorization, a combination that directly affects capital returns and investor sentiment. See our latest analysis for Expeditors International of Washington. The latest news lands after a choppy few weeks for the stock, with a 7 day share price return of a 7.21% decline and a 30 day share price return of a 9.66% decline. Even so, the 1 year total...
NYSE:NOMD
NYSE:NOMDFood

Can Nomad Foods’ (NOMD) Heavy Buybacks and 2026 Reset Realign Its Frozen Food Strategy?

In February 2026, Nomad Foods reported fourth-quarter 2025 results showing sales of €773.1 million versus €793.4 million a year earlier and a net loss of €10.7 million, while completing a €348.46 million buyback that retired 21,397,779 shares, or 13.85% of its share count under a program launched in 2023. Management framed 2026 as a transition year with planned price increases, especially in Fish, and organizational restructuring that are expected to pressure near-term organic sales and...
NasdaqGS:FTRE
NasdaqGS:FTRELife Sciences

A Look At Fortrea Holdings (FTRE) Valuation After Weak Q4 Results And Soft 2025–2026 Guidance

Fortrea Holdings (FTRE) shares came under pressure after the contract research group reported fourth quarter 2025 results with revenue and adjusted earnings below analyst forecasts, along with full year 2025 and 2026 guidance that trailed market expectations. See our latest analysis for Fortrea Holdings. At a share price of US$10.72, Fortrea has recorded a sharp 30 day share price return of a 37.13% decline and a 1 year total shareholder return of a 22.60% loss. This suggests momentum has...